AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts....

+See More

Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 6 December 2025